



INSTITUTIONAL RESEARCH

Healthcare & Biotechnology

TERMINATING COVERAGE

Member FINRA/SIPC

Toll Free: 866-928-0928 ♦ www.DawsonJames.com ♦ 925 Federal Highway, 6th Floor ♦ Boca Raton, FL 33432

A. P. Pharma (Nasdaq/APPA)

Speculative Buy Terminating Coverage

January 2, 2010

Robert M. Wasserman

Director of Research

561-208-2905

rwasserman@dawsonjames.com

Investment Highlights

1) We are terminating coverage on A.P. Pharma due to the termination of the research analyst or analysts covering this stock. Our most recent rating on these shares was Speculative Buy with a price target of \$2.00 per share.

Risk Factors

This company is reliant on overall healthcare spending from **government sources and private payors**, and as such is reliant on **federal and state budgetary processes and the overall economy**. In addition, this Company and/or its clients may be **subject to decisions and inspection by the US FDA and other regulatory agencies**. Finally, this stock may **represent more risk to investors than other, larger and more established equities** available in the overall stock market due to the smaller size, relative unfamiliarity of the shares, and greater risk in operating results or need for additional funding underlying this Company.

Current Price \$1.26

Price Target \$2.00

Estimates	F2008A	F2009E	F2010E
Revenues(\$000s)	\$0.4	\$0.6	\$25.5
EPS	(\$0.80)	N/A	N/A


Stock Data	
52-Week Range	\$0.38-\$1.39
Shares Outstanding (mil.)	39.4
Market Capitalization (mil.)	\$49.6
Enterprise Value (mil.)	\$48.0
Cash (\$Mill)	\$1.6
Long-term debt (\$Mill)	\$0.0
Book Value/Share (9/09)	\$0.01
Price/Book	N/A
Average Trading Volume	84,000
Insider Ownership	53.0%
Institutional Ownership	20.0%
Short interest (Mill)	165,000
Dividend / Yield	\$0.00/0.0%



Price target and ratings changes over the past 3 years:
 Initiated – July 27, 2007 – Speculative Buy – Price Target \$4.50
 Updated – September 30, 2008 – Speculative Buy – Price Target \$2.00

Important Disclosures:

Price Chart:



Price target and ratings changes over the past 3 years:

Initiated – July 27, 2007 – Speculative Buy – Price Target \$4.50

Updated – September 30, 2008 – Speculative Buy – Price Target \$2.00

Analyst Certification: The analyst(s) whose name appears on this research report certifies that 1) all of the views expressed in this report accurately reflect his personal views about any and all of the subject securities or issuers discussed; and 2) no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst in this research report; and 3) All Dawson James employees, including the analyst(s) responsible for preparing this research report, may be eligible to receive non-product or service specific monetary bonus compensation that is based upon various factors, including total revenues of Dawson James and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.

Dawson James has received investment banking compensation from the company mentioned in this report in the past and may actively seek compensation for investment banking services in the future. Dawson James does not make a market in this security. Neither the research analyst whose name appears on this report nor any member of his household is an officer, director or advisory board member of the company. Dawson James did not receive any other compensation from the company in the previous 12 months. The Firm and/or its directors and employees may own securities of the company(s) in this report and may increase or decrease holdings in the future.

Ratings definitions: **1) Buy:** the stock is expected to appreciate and produce a total return of at least 20% over the next 12-18 months; **2) Neutral:** the stock is fairly valued for the next 12-18 months; and **3) Sell:** the stock is expected to decline at least 20% over the next 12-18 months and should be sold.

Ratings Distribution	Company Coverage		Investment Banking	
	# of Companies	% of Total	# of Companies	% of Totals
Buy	13	93%	6	46%
Neutral	1	7%	1	100%
Sell	0	0%	0	0%
Total	14	100%	7	50%

Information about valuation methods and risks can be found in the “STOCK VALUATION” and “RISKS” sections of this report.

DAWSON JAMES SECURITIES, INC., Member SIPC, FINRA, (the "Firm") does not make a market in these securities. The Firm may perform or seek to perform investment banking services for these companies in the future. Analysts receive no direct compensation in connection with the firm's investment banking business. All Dawson James employees, including the analyst(s) responsible for preparing this research report, may be eligible to receive non-product or service specific monetary bonus compensation that is based upon various factors, including total revenues of Dawson James and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report. The Firm, its officers, directors, analysts or employees may effect transactions in and have long or short positions in the securities (or options or warrants with respect thereto) mentioned herein. Although the statements of fact in this report have been obtained from and are based upon recognized statistical services, issuer reports or communications, or other sources that the Firm believes to be reliable, we cannot guarantee their accuracy. All opinions and estimates included in this report constitute the analyst's judgment as of the date of this report and are subject to change without notice. The Firm may effect transactions as principal or agent in the securities mentioned herein. The securities discussed or recommended in this report may be unsuitable for investors depending on their specific investment objectives and financial position. This report is offered for informational purposes only, and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. Additional information is available upon request.